- As adjunctive therapy Keppra XR(TM) offers significant partial onset
seizure reduction, proven tolerability, and once-daily dosing
- Keppra XR(TM) is built on a trusted heritage
ATLANTA, Sept. 15 /PRNewswire/ -- press release, regulated information:
UCB announced today that the U.S. Food and Drug Administration (FDA) has
approved Keppra XR(TM) (levetiracetam extended-release tablets) for use as
an add-on to other antiepileptic treatments for people with partial-onset
seizures who are 16 years of age and older. Keppra XR(TM) is expected to be
available in U.S. pharmacies at the end of September 2008.
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/keppra/34625/
The goal of therapy with antiepileptic drugs (AED) is freedom from seizures and minimal side effects. While many people with epilepsy are successfully treated with one or more of the currently available antiepileptic drugs, a significant percentage still live with uncontrolled seizures or intolerable side effects.
"With solid clinical trial data supporting Keppra XR(TM) efficacy and tolerability, this once-daily antiepileptic drug can play an important role in treating people with epilepsy," said lead investigator Dr. Jukka Peltola, Department of Neurology, Tampere University Hospital, Finland. "We found in the clinical trial that Keppra XR(TM) provided significant partial onset seizure control in once-daily dosing when added to other antiepileptic drugs and that it was generally well-tolerated."
Building On A Trusted Heritage
"This is one of many milestones at UCB to develop new treatment options
for people with epilepsy," said Troy Cox, Senior Vice President UCB &
President CNS Operations. "Keppra XR(TM) provides a way to simplify
treatment and offers another chance to achieve seizure control, which is an
important goal for patie
Copyright©2008 PR Newswire.
All rights reserved